Leidos Biomedical Research, Inc. (LBRI), a wholly owned subsidiary of Leidos, operates the Frederick National Laboratory for Cancer Research (FNLCR). FNLCR is a Federally Funded Research and Development Center (FFRDC) sponsored by the National Cancer Institute (NCI). It is the only FFRDC dedicated to biomedical research. Through its status as an FFRDC, FNLCR provides NCI and others with a unique national resource to accelerate the development and delivery of effective preventive, diagnostic, and therapeutic products for cancer and AIDS.
The breadth of FNLCR’s activities spans the research and development spectrum, including investigator-initiated, hypothesis-driven research into cancer and AIDS; advanced technology programs focused on genetics and genomics, proteins and proteomics, imaging, nanotechnology, bioinformatics, and laboratory animal sciences; clinical operations in support of NCI and National Institute of Allergy and Infectious Diseases (NIAID)-sponsored clinical trials, as well as NCI drug discovery and development efforts; and management and operations of biopharmaceutical development and manufacturing programs under current Good Manufacturing Practice conditions for NCI and NIAID. Administrative, procurement, financial, safety, and facilities support is provided to these R&D activities through state-of-the-art business processes. LBRI has approximately 1,900 employees and manages an annual operating budget of approximately $450M.
For more information about Leidos Biomedical Research Inc., please visit our webpage at www.leidosbiomed.com.
The AIDS and Cancer Virus Program (ACVP) is an integrated, multidisciplinary program that pursues basic and applied studies aimed at improving our understanding of AIDS-associated viruses, including studies intended to facilitate the improved diagnosis, prevention and treatment of HIV infection and AIDS, and AIDS related tumors, particularly those associated with other viruses such as KSHV. The Program consists of five independent but highly interactive research Sections headed by Principal Investigators, whose work spans from fundamental molecular virology through in vitro studies, to in vivo studies in non-human primate (NHP) models, to international viral epidemiology. The ACVP also has eight Research Support Core Groups (Cores) that provide critical and often unique technical support capabilities to ACVP laboratories and other laboratories within the NCI and NIH, and to extramural investigators.
We are looking for a Cellular immunologist /viral immunologist to join out dynamic, interactive, multidisciplinary research team working on AIDS pathogenesis and development of vaccines for prevention of HIV infection and AIDS, working in human and non-human primate systems. The Sr. Scientist will be responsible for: 1) development and execution of hypothesis-driven research plan in HIV/SIV immunology with formal quadrennial reviews, 2) supervision and direction of post-doctoral fellow(s) and technical staff, and 3) management of assigned budget to accomplish research goals.
Ph.D. in a biomedical science (preference cellular immunology/viral immunology)
Foreign degrees must be evaluated for U.S. equivalency
Minimum of five (5) years post-graduate experience
Project management experience in a research setting
Experience with cellular immune assays including: ELISPOT, lymphoproliferation, classical cytotoxicity
Experience with evaluation of vaccine and infection induced antiviral immune responses
Experience working with HIV and /or SIV and/or in characterization of immune responses in non-human primates
Expertise in multiparameter flow cytometry, including intracellular cytokine staining and fluorescence activated cell sorting
First/senior authorships on peer-reviewed publications
Attendance and presentation at national meetings
Experience in the generation and characterization of antigen specific T cell clones
Leidos is an applied solutions company focused on markets that are seeing converging business and technological trends, and address basic, enduring human needs: defense and national security, health and life sciences, and energy, engineering and infrastructure. The Company's approximately 20,000 employees serve customers in the U.S. Department of Defense, the intelligence community, the U.S. Department of Homeland Security, other U.S. Government civil agencies and commercial health and engineering markets. Leidos is an Equal Opportunity Employer.